HighTower Advisors LLC Purchases Shares of 11,201 Hims & Hers Health, Inc. (NYSE:HIMS)

HighTower Advisors LLC acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,201 shares of the company’s stock, valued at approximately $207,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Quest Partners LLC raised its holdings in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after acquiring an additional 807 shares during the last quarter. CWM LLC raised its stake in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of Hims & Hers Health by 3.0% in the second quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock valued at $815,000 after purchasing an additional 1,173 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Hims & Hers Health by 6.6% during the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after buying an additional 1,212 shares in the last quarter. Finally, Rockefeller Capital Management L.P. boosted its holdings in Hims & Hers Health by 5.8% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 33,775 shares of the company’s stock worth $622,000 after acquiring an additional 1,864 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In other news, COO Melissa Baird sold 58,750 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $19.57, for a total transaction of $1,149,737.50. Following the transaction, the chief operating officer now directly owns 630,166 shares of the company’s stock, valued at approximately $12,332,348.62. This trade represents a 8.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total value of $3,943,981.44. Following the transaction, the chief executive officer now owns 67,015 shares in the company, valued at approximately $1,399,273.20. The trade was a 73.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,111,616 shares of company stock valued at $27,448,767. 17.71% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on HIMS. Morgan Stanley started coverage on shares of Hims & Hers Health in a research report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price target on the stock. Canaccord Genuity Group lifted their price target on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price target for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. TD Cowen restated a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $22.80.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $28.15 on Thursday. The business’s fifty day moving average is $26.15 and its 200 day moving average is $21.41. The firm has a market cap of $6.15 billion, a price-to-earnings ratio of 63.98 and a beta of 1.25. Hims & Hers Health, Inc. has a 52-week low of $8.09 and a 52-week high of $35.02.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the prior year, the company posted ($0.04) EPS. The business’s revenue for the quarter was up 77.1% compared to the same quarter last year. Equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.